They cover peptide basics, the preclinical evidence for BPC-157 and TB-500, mechanisms like angiogenesis and tissue repair, the lack of robust human trials, sourcing risks, regulatory bans, and the gap between anecdotal reports and scientific certainty
Local subcutaneous injection near the shoulder if possible, otherwise systemic Optional TB-500: 500 to 750 mcg twice weekly for systemic support Optional GHK-Cu: 200 to 400 mcg daily, added from week three onward for collagen quality Duration: Eight to twelve weeks Critical addition: Physical therapy and progressive loading
- Sold from a Licenced Pharmacy in Canada - can be used to reconstitute peptides
10.1002/path.2277 153 XueX
While B12 injections do work, sublingual vitamin B12 has been shown to be more efficient in boosting B12 levels, especially in patients with deficiency
So the conceptual difference is straightforward: GLOW = GHK-Cu + BPC-157 + TB-500 (gene expression + angiogenesis + cell migration) KLOW = GHK-Cu + BPC-157 + TB-500 + KPV (adds an anti-inflammatory component) KLOW is studied when researchers want the GLOW base plus a dedicated anti-inflammatory peptide in the same formulation
